Like so many other drugmakers, BioNTech saw its total revenues drop significantly due to the waning demand for COVID-19 vaccines and treatments.
The German biotech reported €167.7 million in total revenues for the quarter, down from €3.2 billion this time last year.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,